InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the complete record of transactions filed by Rottinghaus Scott T.. Director active across 1 company, notably Enanta Pharmaceuticals INC. In total, 12 reports have been logged. Breakdown: 0 buy · 4 sells. Total volume traded: €81k. History available since 8 August 2022. The latest transaction was disclosed on 8 August 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations
Rottinghaus Scott T. is Chief Medical Officer at Enanta Pharmaceuticals INC (XNAS). He has 11 filings in total, and across the 11 most recent filings we hold, the transactions run from 2022-08-11 to 2026-02-13, with sum_sell_eur at 80678 and sum_buy_eur at 0, and the modal transaction nature is Attribution.